Eltrombopag reduces clinically relevant thrombocytopenic events in higher risk MDS and AML
Mené sur 162 patients atteints d'une leucémie myéloïde aiguë ou d'un syndrome myélodysplasique de stade avancé, cet essai de phase II évalue l'efficacité et la toxicité de l'eltrombopag, un agoniste du récepteur de la thrombopoïétine, pour traiter une thrombopénie sévère, en combinaison avec des soins de support
Thrombocytopenia is a significant cause of morbidity and mortality in myelodysplastic syndromes (MDS) and is independently associated with a poor prognosis. The treatment of thrombocytopenia in higher-risk MDS and acute myeloid leukemia (AML) remains challenging because none of the approved chemotherapeutic agents for the treatment of this disease have shown a consistent ability in improving platelets counts. Instead, most of these drugs can cause significant treatment-related thrombocytopenia.1 The thrombopoietin receptor agonists, eltrombopag and romiplostim, have shown signs of clinical activity in MDS clinical trials, however, robust outcome data on the use of these agents in higher-risk MDS and AML are absent.
The Lancet Haematology , commentaire, 2016